181 related articles for article (PubMed ID: 27863652)
1. Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model.
Leite Nascimento T; Hillaireau H; Vergnaud J; Rivano M; Deloménie C; Courilleau D; Arpicco S; Suk JS; Hanes J; Fattal E
Int J Pharm; 2016 Nov; 514(1):103-111. PubMed ID: 27863652
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
3. Mucopenetrating lipoplexes modified with PEG and hyaluronic acid for CD44-targeted local siRNA delivery to the lungs.
Almeida APB; Damaceno GBR; Carneiro AF; Bohr A; Gonçalves HR; Valadares MC; Nascimento TL; Lima EM
J Biomater Appl; 2019 Nov; 34(5):617-630. PubMed ID: 31357900
[No Abstract] [Full Text] [Related]
4. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.
Zhang W; Xu W; Lan Y; He X; Liu K; Liang Y
Int J Nanomedicine; 2019; 14():5287-5301. PubMed ID: 31406460
[No Abstract] [Full Text] [Related]
6. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
Ganesh S; Iyer AK; Morrissey DV; Amiji MM
Biomaterials; 2013 Apr; 34(13):3489-502. PubMed ID: 23410679
[TBL] [Abstract][Full Text] [Related]
8. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor.
Dufaÿ Wojcicki A; Hillaireau H; Nascimento TL; Arpicco S; Taverna M; Ribes S; Bourge M; Nicolas V; Bochot A; Vauthier C; Tsapis N; Fattal E
J Control Release; 2012 Sep; 162(3):545-52. PubMed ID: 22820451
[TBL] [Abstract][Full Text] [Related]
10. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells.
Surace C; Arpicco S; Dufaÿ-Wojcicki A; Marsaud V; Bouclier C; Clay D; Cattel L; Renoir JM; Fattal E
Mol Pharm; 2009; 6(4):1062-73. PubMed ID: 19413341
[TBL] [Abstract][Full Text] [Related]
11. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
12. Supramolecular Organization and siRNA Binding of Hyaluronic Acid-Coated Lipoplexes for Targeted Delivery to the CD44 Receptor.
Nascimento TL; Hillaireau H; Noiray M; Bourgaux C; Arpicco S; Pehau-Arnaudet G; Taverna M; Cosco D; Tsapis N; Fattal E
Langmuir; 2015 Oct; 31(41):11186-94. PubMed ID: 26375384
[TBL] [Abstract][Full Text] [Related]
13. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-fabricated nanogold delivery of the inhibitor of apoptosis protein-2 siRNAs inhibits benzo[a]pyrene-induced oncogenic properties of lung cancer A549 cells.
Lin CM; Kao WC; Yeh CA; Chen HJ; Lin SZ; Hsieh HH; Sun WS; Chang CH; Hung HS
Nanotechnology; 2015 Mar; 26(10):105101. PubMed ID: 25693888
[TBL] [Abstract][Full Text] [Related]
15. Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties.
Yin T; Liu J; Zhao Z; Dong L; Cai H; Yin L; Zhou J; Huo M
J Control Release; 2016 Dec; 243():54-68. PubMed ID: 27702595
[TBL] [Abstract][Full Text] [Related]
16. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS.
Cardoso AL; Simões S; de Almeida LP; Plesnila N; Pedroso de Lima MC; Wagner E; Culmsee C
J Control Release; 2008 Dec; 132(2):113-23. PubMed ID: 18796321
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes.
Qhattal HS; Liu X
Mol Pharm; 2011 Aug; 8(4):1233-46. PubMed ID: 21696190
[TBL] [Abstract][Full Text] [Related]
18. Effect of hyaluronic acid-binding to lipoplexes on intravitreal drug delivery for retinal gene therapy.
Martens TF; Peynshaert K; Nascimento TL; Fattal E; Karlstetter M; Langmann T; Picaud S; Demeester J; De Smedt SC; Remaut K; Braeckmans K
Eur J Pharm Sci; 2017 May; 103():27-35. PubMed ID: 28223236
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal Macrophage-Specific TNF-α Gene Silencing in LPS-Induced Acute Inflammation Model Using CD44 Targeting Hyaluronic Acid Nanoparticles.
Kosovrasti VY; Nechev LV; Amiji MM
Mol Pharm; 2016 Oct; 13(10):3404-3416. PubMed ID: 27552547
[TBL] [Abstract][Full Text] [Related]
20. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
